{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:32:40Z","timestamp":1779114760246,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870988"],"award-info":[{"award-number":["81870988"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82071410"],"award-info":[{"award-number":["82071410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["2018SHZDZX01"],"award-info":[{"award-number":["2018SHZDZX01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>An accurate prediction for prognosis can help in guiding the therapeutic options and optimizing the trial design for generalized myasthenia gravis (gMG). We aimed to develop and validate a predictive nomogram to assess the short-term outcome in patients with the anti-acetylcholine receptor (AChR) subtype gMG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed 165 patients with AChR subtype gMG who were immunotherapy na\u00efve at the first visit from five tertiary centers in China. The short-term clinical outcome is defined as the achievement of minimal symptom expression (MSE) at 12\u00a0months. Of them, 120 gMG patients from Huashan Hospital were enrolled to form a derivation cohort (n\u2009=\u200996) and a temporal validation cohort (n\u2009=\u200924) for the nomogram. Then, this nomogram was externally validated using 45 immunotherapy na\u00efve AChR subtype gMG from the other four hospitals. Multivariate logistic regression was used to screen independent factors and construct the nomogram.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MSE was achieved in 70 (72.9%), 20 (83.3%), and 33 (73.3%) patients in the training, temporal validation, and external validation cohort, respectively. The duration\u2009\u2264\u200912\u00a0months (<jats:italic>p<\/jats:italic>\u2009=\u20090.021), ocular score\u2009\u2264\u20092 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006), QMG score\u2009&gt;\u200913 (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), and gross motor score\u2009\u2264\u20099 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006) were statistically associated with MSE in AChR subtype gMG. The nomogram has good performance in predicting MSE as the concordance indexes are 0.81 (95% CI, 0.72\u20130.90) in the development cohort, 0.944 (95% CI, 0.83\u20131.00) in the temporal validation cohort, and 0.773 (95% CI, 0.63\u20130.92) in the external validation cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The nomogram achieved an optimal prediction of MSE in AChR subtype gMG patients using the baseline clinical characters.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-021-02961-9","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:03:23Z","timestamp":1625054603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis"],"prefix":"10.1186","volume":"19","author":[{"given":"Rui","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huahua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9033-7568","authenticated-orcid":false,"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"2961_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"2961_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","volume":"36","author":"MK Hehir","year":"2018","unstructured":"Hehir MK, Silvestri NJ. Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology. Neurol Clin. 2018;36:253\u201360.","journal-title":"Neurol Clin"},{"key":"2961_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","volume":"26","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054\u20139.","journal-title":"Neurology"},{"key":"2961_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cns.13110","volume":"25","author":"L Wang","year":"2019","unstructured":"Wang L, Huan X, Xi J-Y, Wu H, Zhou L, Lu J-H, Zhang T-S, Zhao C-B. Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: a network meta-analysis. CNS Neurosci Ther. 2019;25:647\u201358.","journal-title":"CNS Neurosci Ther"},{"key":"2961_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jns.2018.10.018","volume":"396","author":"T Kanai","year":"2019","unstructured":"Kanai T, Uzawa A, Kawaguchi N, Oda F, Ozawa Y, Himuro K, Kuwabara S. Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis. J Neurol Sci. 2019;396:8\u201311.","journal-title":"J Neurol Sci"},{"key":"2961_CR6","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1468-1331.2010.03017.x","volume":"17","author":"ZF Mao","year":"2010","unstructured":"Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol. 2010;17:913\u201321.","journal-title":"Eur J Neurol"},{"key":"2961_CR7","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP, O\u2019Brien F, Howard JF. \u201cMinimal symptom expression\u201d in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020;267:1991\u20132001.","journal-title":"J Neurol"},{"key":"2961_CR8","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido F, Piehl F, Rottoli M, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92:e2661\u201373.","journal-title":"Neurology"},{"key":"2961_CR9","doi-asserted-by":"publisher","first-page":"116428","DOI":"10.1016\/j.jns.2019.116428","volume":"406","author":"TM Nguyen-Cao","year":"2019","unstructured":"Nguyen-Cao TM, Gelinas D, Griffin R, Mondou E. Myasthenia gravis: historical achievements and the \u201cgolden age\u201d of clinical trials. J Neurol Sci. 2019;406:116428.","journal-title":"J Neurol Sci"},{"key":"2961_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19:335.","journal-title":"BMC Neurol"},{"key":"2961_CR11","doi-asserted-by":"crossref","unstructured":"2020 Virtual AANEM Annual Meeting Abstract Guide. Muscle Nerve 2020, 62 Suppl 1:S1-S131.","DOI":"10.1002\/mus.27054"},{"key":"2961_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, Nakamura Y, Kawaguchi N, Onodera H, Araga S, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci. 2011;305:97\u2013102.","journal-title":"J Neurol Sci"},{"key":"2961_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","volume":"11","author":"SM Hayter","year":"2012","unstructured":"Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11:754\u201365.","journal-title":"Autoimmun Rev"},{"key":"2961_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/0028-3886.144438","volume":"62","author":"SV Khadilkar","year":"2014","unstructured":"Khadilkar SV, Chaudhari CR, Patil TR, Desai ND, Jagiasi KA, Bhutada AG. Once myasthenic, always myasthenic? observations on the behavior and prognosis of myasthenia gravis in a cohort of 100 patients. Neurol India. 2014;62:492\u20137.","journal-title":"Neurol India"},{"key":"2961_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1749-6632.1976.tb47676.x","volume":"274","author":"AG Engel","year":"1976","unstructured":"Engel AG, Tsujihata M, Lindstrom JM, Lennon VA. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci. 1976;274:60\u201379.","journal-title":"Ann N Y Acad Sci"},{"key":"2961_CR16","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.23236","volume":"45","author":"HD Katzberg","year":"2012","unstructured":"Katzberg HD, Barnett C, Bril V. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve. 2012;45:648\u201352.","journal-title":"Muscle Nerve"},{"key":"2961_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55:16\u201323.","journal-title":"Neurology"},{"key":"2961_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37:141\u20139.","journal-title":"Muscle Nerve"},{"key":"2961_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10520-x","author":"Y Ozawa","year":"2021","unstructured":"Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Onishi Y, Oda F, Kanai T, Himuro K, Kawaguchi N, Kuwabara S. Long-term outcomes and prognostic factors in generalized myasthenia gravis. J Neurol. 2021. https:\/\/doi.org\/10.1007\/s00415-021-10520-x.","journal-title":"J Neurol"},{"key":"2961_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44:727\u201331.","journal-title":"Muscle Nerve"},{"key":"2961_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06817.x","volume":"1274","author":"S Muppidi","year":"2012","unstructured":"Muppidi S. The myasthenia gravis\u2013specific activities of daily living profile. Ann N Y Acad Sci. 2012;1274:114\u20139.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-021-02961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-021-02961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:12:29Z","timestamp":1625055149000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-021-02961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2961"],"URL":"https:\/\/doi.org\/10.1186\/s12967-021-02961-9","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of each hospital. Written informed consent was obtained from each study participant before sample collection. All study procedures were performed by the principles of Good Clinical Practice and the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"285"}}